{"id":"bms-650032","safety":{"commonSideEffects":[{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Hypothyroidism"},{"rate":"null","effect":"Hyperthyroidism"}]},"_chembl":{"chemblId":"CHEMBL4303322","moleculeType":"Small molecule","molecularWeight":"518.51"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the PD-1 receptor, BMS-650032 allows T cells to recognize and attack cancer cells more effectively. This mechanism is similar to other PD-1 inhibitors, such as nivolumab and pembrolizumab, which have shown efficacy in various types of cancer.","oneSentence":"BMS-650032 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells to enhance anti-tumor immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:25:16.317Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT02583685","phase":"PHASE2","title":"Switching Regimen in Treating Cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05-15","conditions":"Chronic Hepatitis C Infection","enrollment":138},{"nctId":"NCT03208322","phase":"","title":"Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2018-11-30","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT03071133","phase":"","title":"Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-01-01","conditions":"Hepatitis C","enrollment":344},{"nctId":"NCT02727933","phase":"","title":"Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-11-03","conditions":"Hepatitis C","enrollment":1941},{"nctId":"NCT04952207","phase":"","title":"Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Qing XIe","startDate":"2019-03-06","conditions":"Hepatitis C, Chronic","enrollment":300},{"nctId":"NCT02170727","phase":"PHASE3","title":"A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-06-26","conditions":"Hepatitis C Virus","enrollment":199},{"nctId":"NCT01995266","phase":"PHASE3","title":"Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-02-28","conditions":"Hepatitis C","enrollment":218},{"nctId":"NCT02175966","phase":"PHASE2","title":"Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-07-28","conditions":"Hepatitis C","enrollment":35},{"nctId":"NCT03794258","phase":"PHASE2","title":"Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection","status":"WITHDRAWN","sponsor":"Humanity & Health Medical Group Limited","startDate":"2019-05-01","conditions":"HCV Infection","enrollment":""},{"nctId":"NCT01492504","phase":"","title":"Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-02-07","conditions":"Hepatitis C","enrollment":1850},{"nctId":"NCT03887637","phase":"","title":"Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-03-30","conditions":"Chronic Hepatitis C","enrollment":180},{"nctId":"NCT03004625","phase":"PHASE3","title":"Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2016-11","conditions":"Hepatitis C","enrollment":70},{"nctId":"NCT02580474","phase":"PHASE4","title":"The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure","status":"COMPLETED","sponsor":"Myeong Jun Song","startDate":"2016-02","conditions":"Hepatitis C","enrollment":21},{"nctId":"NCT02762448","phase":"","title":"Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas","status":"WITHDRAWN","sponsor":"Tainan Municipal Hospital","startDate":"2016-07","conditions":"Hepatitis c","enrollment":""},{"nctId":"NCT02124044","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2014-02","conditions":"HIV-HCV","enrollment":30},{"nctId":"NCT02250001","phase":"","title":"Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-09-30","conditions":"Chronic Hepatitis C","enrollment":2974},{"nctId":"NCT01455090","phase":"PHASE2","title":"Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-11-30","conditions":"Chronic Hepatitis C","enrollment":320},{"nctId":"NCT02496078","phase":"PHASE3","title":"A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-08","conditions":"Hepatitis C","enrollment":207},{"nctId":"NCT02865369","phase":"","title":"Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment","status":"UNKNOWN","sponsor":"Sang Gyune Kim","startDate":"2016-09","conditions":"Chronic Hepatitis C","enrollment":103},{"nctId":"NCT01888900","phase":"PHASE2","title":"New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2013-05","conditions":"Cirrhosis, Chronic Hepatitis C, Hepatitis C","enrollment":35},{"nctId":"NCT02107365","phase":"PHASE2","title":"Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2013-11","conditions":"Hepatitis C Virus Genotype 4 Infection","enrollment":60},{"nctId":"NCT02292966","phase":"PHASE4","title":"Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism","status":"WITHDRAWN","sponsor":"Kirby Institute","startDate":"2015-07","conditions":"Hepatitis C, Chronic","enrollment":""},{"nctId":"NCT01428063","phase":"PHASE2","title":"Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-09","conditions":"Hepatitis C Virus Infection","enrollment":276},{"nctId":"NCT02098616","phase":"NA","title":"Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus","status":"COMPLETED","sponsor":"Timothy Morgan, MD","startDate":"2014-07","conditions":"Hepatitis C","enrollment":25},{"nctId":"NCT02470858","phase":"PHASE2","title":"Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-01","conditions":"Chronic Hepatitis C Infection","enrollment":18},{"nctId":"NCT02309450","phase":"PHASE2","title":"Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen","status":"WITHDRAWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-12","conditions":"Hepatitis C Virus Genotype 4 Infection","enrollment":""},{"nctId":"NCT02639585","phase":"PHASE4","title":"Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Pusan National University Hospital","startDate":"2015-12","conditions":"Hepatitis C, Chronic","enrollment":32},{"nctId":"NCT01979939","phase":"PHASE3","title":"UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-12","conditions":"Hepatitis C","enrollment":416},{"nctId":"NCT02282709","phase":"PHASE3","title":"Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2014-02","conditions":"Chronic Hepatitis C","enrollment":12},{"nctId":"NCT01309932","phase":"PHASE2","title":"Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-03","conditions":"Hepatitis C","enrollment":165},{"nctId":"NCT01573351","phase":"PHASE3","title":"Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C Virus","enrollment":398},{"nctId":"NCT01718145","phase":"PHASE3","title":"A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-11","conditions":"Hepatitis C Virus Infection","enrollment":258},{"nctId":"NCT01051414","phase":"PHASE2","title":"An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-04","conditions":"Hepatitis C Infection","enrollment":43},{"nctId":"NCT01030432","phase":"PHASE2","title":"Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-02","conditions":"Hepatitis C Virus","enrollment":285},{"nctId":"NCT01973049","phase":"PHASE3","title":"UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-12","conditions":"Hepatitis C","enrollment":202},{"nctId":"NCT01795911","phase":"PHASE2","title":"Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-03","conditions":"Hepatitis C","enrollment":165},{"nctId":"NCT01497834","phase":"PHASE3","title":"A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-01","conditions":"Hepatitis C","enrollment":224},{"nctId":"NCT01581203","phase":"PHASE3","title":"Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C Virus","enrollment":748},{"nctId":"NCT01012895","phase":"PHASE2","title":"Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Chronic Hepatitis C","enrollment":215},{"nctId":"NCT02123654","phase":"PHASE3","title":"UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-04","conditions":"Hepatitis C Virus Infection","enrollment":297},{"nctId":"NCT02323594","phase":"PHASE1","title":"A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-12","conditions":"Hepatitis C Infection","enrollment":88},{"nctId":"NCT02175602","phase":"PHASE1","title":"Study of Drug Combination on Pharmacokinetics in Healthy Volunteers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-06","conditions":"Hepatitis C Infection","enrollment":41},{"nctId":"NCT02095860","phase":"PHASE1","title":"Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-04","conditions":"Hepatitis C","enrollment":24},{"nctId":"NCT01725542","phase":"PHASE2","title":"Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2012-12","conditions":"HCV-HIV Co-Infection","enrollment":75},{"nctId":"NCT02103569","phase":"PHASE1","title":"Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-04","conditions":"Hepatitis C","enrollment":20},{"nctId":"NCT02104843","phase":"PHASE1","title":"Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-04","conditions":"Hepatitis C","enrollment":18},{"nctId":"NCT02108639","phase":"PHASE1","title":"To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-04","conditions":"Hepatitis C","enrollment":41},{"nctId":"NCT02045966","phase":"PHASE1","title":"Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-02","conditions":"Hepatitis C","enrollment":16},{"nctId":"NCT02045693","phase":"PHASE1","title":"Drug Interaction & Methadone & Buprenorphine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-02","conditions":"Hepatitis C","enrollment":32},{"nctId":"NCT01886599","phase":"PHASE1","title":"Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-11","conditions":"Hepatitis C","enrollment":48},{"nctId":"NCT01019070","phase":"PHASE1","title":"Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Hepatic Insufficiency","enrollment":28},{"nctId":"NCT00722358","phase":"PHASE2","title":"A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-12","conditions":"Chronic Hepatitis C","enrollment":15},{"nctId":"NCT01063023","phase":"PHASE1","title":"Drug Interaction Oral Contraceptive Pill (OCP)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-01","conditions":"Hepatitis C Virus","enrollment":20},{"nctId":"NCT00904059","phase":"PHASE1","title":"Drug-Drug Interaction Study in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-05","conditions":"Hepatitis C","enrollment":28},{"nctId":"NCT00559247","phase":"PHASE1, PHASE2","title":"A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-01","conditions":"Chronic Hepatitis C","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Asunaprevir (ASV)"],"phase":"phase_2","status":"active","brandName":"BMS-650032","genericName":"BMS-650032","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BMS-650032 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells to enhance anti-tumor immune response. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}